IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, May 2024

Herbal Innovations in Eczema Care: A Comprehensive Review of Formulation Development, Safety, and Efficacy

Aakash Babasaheb Chalge, Dr. H. A. Sawarkar, Dr. K. R. Biyani
Anuradha College of Pharmacy, Chikhli, Buldhana, India

Abstract: *Eczema, also known as atopic dermatitis, presents a significant challenge in clinical management due to its multifactorial etiology and variable clinical manifestations. Conventional treatments often focus on symptom relief and inflammation control, yet concerns regarding their long-term safety and efficacy persist. In recent years, there has been growing interest in exploring herbal therapies as adjunctive or alternative treatments for eczema management. This review aims to provide a comprehensive overview of the development and evaluation of topical herbal formulations specifically targeted at managing infectious eczema. Beginning with an introduction to eczema, encompassing its prevalence, underlying pathophysiology, and conventional treatment modalities, the review sets the stage for exploring the potential of herbal therapies. It delves into the significance of herbal treatments in eczema care, emphasizing their potential advantages such as efficacy, safety, and patient acceptability. The review then outlines the systematic approach to formulation development, encompassing the selection of herbal ingredients, optimization of base formulations, and rigorous stability testing. Safety evaluation strategies, including toxicological assessments, skin irritation potential, and allergenicity testing, are discussed to ensure the safety and tolerability of the herbal formulations. Efficacy evaluation involves assessing anti-inflammatory properties, antimicrobial activity, and conducting well-controlled clinical trials to determine their clinical efficacy and impact on patient outcomes. Through a comprehensive discussion and analysis, this review aims to elucidate the potential of topical herbal formulations as promising therapeutic options for managing infectious eczema, while also identifying areas for further research and optimization*

Keywords: Eczema, atopic dermatitis, herbal therapies, topical formulations, infectious eczema, anti-inflammatory, antimicrobial, clinical efficacy

I. INTRODUCTION

Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition characterized by itching, redness, and skin lesions [1]. It affects individuals of all ages, with a prevalence that has been steadily increasing worldwide [2]. The etiology of eczema is complex, involving genetic predispositions, immune dysregulation, environmental factors, and skin barrier dysfunction [3].

Despite the availability of conventional treatments such as corticosteroids and immunosuppressants, managing eczema remains a challenge for both patients and healthcare providers. These treatments often come with limitations such as side effects, temporary relief, and the risk of microbial resistance [4]. As a result, there is growing interest in exploring alternative therapies, particularly those derived from natural sources like herbal formulations.

Herbal therapies have been utilized for centuries in various cultures for the treatment of skin ailments, including eczema. Plants contain a rich array of bioactive compounds with potential anti-inflammatory, antimicrobial, and skin-soothing properties [5]. Additionally, herbal remedies are often perceived as safer and more holistic alternatives to conventional medications, driving their popularity among eczema sufferers [6].

This review aims to provide a comprehensive overview of the development, safety, and efficacy of a novel topical herbal formulation for managing infectious eczema. By synthesizing existing knowledge and presenting new insights, this review seeks to contribute to the growing body of literature on herbal innovations in eczema care.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, May 2024

A. Background on Eczema

Eczema, or atopic dermatitis, is a prevalent chronic inflammatory skin condition characterized by itching, redness, and skin lesions. It is a multifactorial disorder involving complex interactions between genetic predispositions, immune dysregulation, environmental factors, and impaired skin barrier function [7,8].

The pathogenesis of eczema involves dysfunction in the skin barrier, which allows for increased trans-epidermal water loss and penetration of irritants, allergens, and microbes. This disruption triggers an inflammatory response mediated by T cells, cytokines, and other immune cells, leading to the characteristic symptoms of eczema [9,10].

Eczema can manifest at any age, but it often begins in infancy or early childhood. It is commonly associated with other atopic conditions such as asthma and allergic rhinitis, suggesting a shared underlying mechanism of allergic inflammation [3]. The prevalence of eczema has been steadily increasing worldwide, affecting up to 20% of children and 3% of adults in industrialized countries [11,12].

The clinical presentation of eczema varies widely, ranging from mild itching and erythema to severe, debilitating lesions with oozing and crusting. Common sites of involvement include the face, neck, flexural areas, and extremities, although any part of the body can be affected. The chronic nature of eczema can have a significant impact on patients' quality of life, leading to sleep disturbances, psychological distress, and social isolation [13].

Management of eczema typically involves a combination of skincare measures, topical medications, and in severe cases, systemic therapies. Topical corticosteroids and calcineurin inhibitors are the mainstay of treatment for controlling inflammation and relieving symptoms. However, concerns about long-term safety and efficacy have prompted interest in alternative therapies, including herbal formulations [14,15].

In recent years, there has been growing interest in herbal remedies for eczema due to their perceived safety, tolerability, and potential efficacy. Plant-derived compounds such as flavonoids, terpenoids, and polyphenols have demonstrated anti-inflammatory, antimicrobial, and antioxidant properties that may benefit eczema patients [16]. Herbal therapies offer a promising adjunctive or alternative approach to conventional treatments, providing patients with additional options for managing their condition.

B. Significance of Herbal Therapies

Herbal therapies have garnered significant attention in recent years due to their perceived safety, tolerability, and potential efficacy in treating various medical conditions, including eczema. The use of herbal remedies dates back thousands of years and is deeply rooted in traditional medicine systems across different cultures worldwide.

One of the primary reasons for the growing interest in herbal therapies for eczema is the limitations and concerns associated with conventional treatments. While topical corticosteroids and calcineurin inhibitors are effective in managing eczema symptoms, they may also carry risks of adverse effects such as skin thinning, striae formation, and systemic absorption [17]. Additionally, long-term use of these medications can lead to tachyphylaxis and rebound flare-ups upon discontinuation [18]. As a result, patients and healthcare providers are increasingly seeking alternative, natural treatment options with fewer side effects.

Herbal therapies offer a diverse array of bioactive compounds with potential therapeutic benefits for eczema. Many plants contain phytochemicals such as flavonoids, terpenoids, and polyphenols, which exhibit anti-inflammatory, antimicrobial, antioxidant, and skin-soothing properties [19]. For example, chamomile (Matricaria chamomilla) contains chamazulene and α-bisabolol, which have anti-inflammatory effects and can help alleviate itching and irritation associated with eczema [20]. Similarly, calendula (Calendula officinalis) has been shown to possess wound-healing and anti-inflammatory properties, making it a popular ingredient in topical formulations for eczema [21].

In addition to their therapeutic effects, herbal therapies are often perceived as holistic approaches to health and wellness. Many individuals prefer natural remedies derived from plants over synthetic medications due to their perceived gentleness on the body and alignment with nature. This holistic approach considers not only the physical symptoms of eczema but also the emotional and psychological aspects, promoting overall well-being and quality of life for patients.

Moreover, herbal therapies offer a personalized and patient-centered approach to eczema management. Each individual may respond differently to herbal remedies based on their unique physiology, skin type, and underlying health

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, May 2024

conditions. This personalized approach allows for tailored treatment plans that address the specific needs and preferences of patients, fostering a sense of empowerment and self-care.

Overall, the significance of herbal therapies in eczema care lies in their potential to provide effective, natural, and holistic alternatives to conventional treatments. By harnessing the healing power of plants, herbal remedies offer promising avenues for managing eczema symptoms and improving the quality of life for affected individuals.

C. Purpose of the Review

The purpose of this review is to provide a comprehensive evaluation of a novel topical herbal formulation designed for managing infectious eczema. The review aims to synthesize existing knowledge and research findings related to the development, safety, and efficacy of herbal therapies in the context of eczema management, with a specific focus on infectious forms of the condition.

Review of Formulation Development: The review will outline the process of formulating the topical herbal product, including the selection of herbal ingredients, base formulation considerations, and methodology employed in the development process. By examining the formulation development in detail, the review seeks to elucidate the rationale behind ingredient selection and the potential synergistic effects of the herbal components.

Safety Evaluation: A critical aspect of the review will be the assessment of the safety profile of the herbal formulation. This will involve a thorough examination of toxicological considerations, skin irritation potential, allergenicity evaluation, and other relevant safety parameters. By analyzing the safety data, the review aims to provide insights into the tolerability and potential adverse effects associated with the herbal product.

Efficacy Evaluation: Another key focus of the review will be the evaluation of the efficacy of the herbal formulation in managing infectious eczema. This will include an assessment of its anti-inflammatory properties, antimicrobial activity, and clinical efficacy based on available evidence from preclinical studies, in vitro experiments, and clinical trials. By examining the efficacy data, the review seeks to ascertain the therapeutic potential of the herbal product in alleviating symptoms and combating infection associated with eczema.

Implications for Clinical Practice and Research: Finally, the review will discuss the implications of the findings for clinical practice and future research directions. This will involve a critical appraisal of the strengths and limitations of the herbal formulation, as well as recommendations for its use in real-world settings. By providing practical insights and guidance, the review aims to inform healthcare providers, researchers, and patients about the potential role of herbal therapies in the management of infectious eczema.

Overall, the purpose of this review is to contribute to the understanding of herbal innovations in eczema care and to facilitate evidence-based decision-making regarding the use of herbal formulations in clinical practice. Through a comprehensive evaluation of formulation development, safety, and efficacy, the review aims to provide valuable insights into the therapeutic potential of herbal therapies for managing infectious eczema.

II. FORMULATION DEVELOPMENT

Formulating a topical herbal product for managing infectious eczema involves a systematic approach that integrates scientific knowledge of herbal ingredients, base formulation considerations, and methodological techniques. This section outlines the key steps involved in the formulation development process.

A. Selection of Herbal Ingredients:

Literature Review: Conduct a comprehensive review of the scientific literature to identify herbal ingredients with documented anti-inflammatory, antimicrobial, and skin-soothing properties relevant to eczema management.

Evidence-Based Selection: Based on the literature review, select herbal ingredients known for their efficacy in addressing the symptoms of eczema and combating microbial infections. Examples may include chamomile, calendula, licorice root, and aloe vera.

Synergistic Effects: Consider the potential synergistic effects of combining multiple herbal ingredients to enhance therapeutic efficacy and broaden the spectrum of activity against infectious agents implicated in eczema.[22,23]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, May 2024

Table 1: Common herbs used in eczema[24]

Herb Name	Scientific Name	Family	Chemical Constituent	Uses
Chamomile	Matricaria chamomilla	Asteraceae	Chamazulene, α-bisabolol	Anti-inflammatory, soothing, antimicrobial
Calendula	Calendula officinalis	Asteraceae	Flavonoids, saponins	Wound healing, anti-inflammatory
Licorice	Glycyrrhiza glabra	Fabaceae	Glycyrrhizin	Anti-inflammatory, antioxidant
Aloe Vera	Aloe barbadensis	Asphodelaceae	Polysaccharides	Moisturizing, wound healing
Turmeric	Curcuma longa	Zingiberaceae	Curcuminoids	Anti-inflammatory, antioxidant
Lavender	Lavandula angustifolia	Lamiaceae	Linalool, linalyl acetate	Calming, anti-inflammatory
Tea Tree	Melaleuca alternifolia	Myrtaceae	Terpinen-4-ol	Antimicrobial, anti-inflammatory
Evening Primrose	Oenothera biennis	Onagraceae	Gamma-linolenic acid (GLA)	Skin barrier repair, anti-inflammatory
Witch Hazel	Hamamelis virginiana	Hamamelidaceae	Tannins	Astringent, anti-inflammatory
Neem	Azadirachta indica	Meliaceae	Azadirachtin, nimbidin	Antimicrobial, anti-inflammatory

B. Base Formulation Considerations:

Compatibility: Ensure compatibility between the selected herbal ingredients and the chosen base formulation (e.g., cream, ointment, or lotion) to achieve optimal stability and efficacy.

Skin Penetration: Select a base formulation that facilitates the penetration of herbal actives into the skin to exert their therapeutic effects at the site of inflammation and infection.

Texture and Absorption: Take into account the desired texture, viscosity, and absorption rate of the formulation to optimize patient compliance and comfort during application.[25]

Table 2: Common base formulations used in topical preparations[26]

Base Formulation	Description
Cream	Emulsion of water and oil, often light and easily spreadable, suitable for moderate hydration of the skin.
Ointment	Semi-solid preparation with a higher lipid content, providing occlusion and intense hydration of the skin.
Lotion	A liquid preparation containing water and oil, typically lighter than creams, suitable for larger areas.
Gel	Semi-solid or liquid preparation containing a gelling agent, offering cooling and hydrating properties.
Balm	Thick, oily preparation with a higher concentration of lipids, providing intense nourishment to the skin.
Lotion	A liquid preparation containing water and oil, typically lighter than creams, suitable for larger areas.

C. Methodology in Formulation Development

- **Laboratory Scale Formulation**: Develop the initial formulation on a laboratory scale, carefully weighing and blending the herbal ingredients with the base formulation using standardized protocols.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, May 2024

- **Optimization Studies**: Conduct optimization studies to refine the formulation parameters, such as concentration of herbal actives, pH, and viscosity, to achieve the desired therapeutic properties and sensory attributes.
- **Stability Testing**: Evaluate the stability of the formulated product under various storage conditions (e.g., temperature, humidity) to ensure product integrity and shelf-life stability.
- **Quality Control Measures**: Implement rigorous quality control measures to monitor the consistency and purity of the formulation, including testing for microbial contamination, heavy metals, and other contaminants.

By following a systematic approach to formulation development, including evidence-based selection of herbal ingredients, careful consideration of base formulation characteristics, and methodological rigor in optimization and quality control, a novel topical herbal product for managing infectious eczema can be developed with the potential for safety and efficacy in clinical use.[27,28]

III. SAFETY EVALUATION

A. Overview of Safety Assessment:

Safety assessment is a crucial step in the development of any therapeutic product, including topical herbal formulations for managing infectious eczema. This involves evaluating the potential risks associated with the formulation and ensuring its safety for use in clinical settings.

B. Toxicological Considerations:

Toxicological considerations involve assessing the potential toxicity of the herbal formulation and its individual components. This includes evaluating acute and chronic toxicity, genotoxicity, carcinogenicity, and reproductive toxicity through in vitro and in vivo studies. Toxicological assessments help ensure that the formulation does not pose undue harm to users.

C. Skin Irritation Potential:

Skin irritation potential is an important aspect of safety evaluation, particularly for topical products intended for application to the skin. Assessments such as the Draize patch test and human repeated insult patch test (HRIPT) are conducted to determine the potential for irritation or sensitization reactions in human subjects. These tests help identify any adverse skin reactions that may occur upon application of the formulation.

D. Allergenicity Evaluation:

Allergenicity evaluation involves assessing the potential for allergic reactions to the herbal formulation or its components. This may include conducting skin prick tests, patch tests, or in vitro assays to identify allergens and evaluate their sensitizing potential. Allergenicity assessments are essential for identifying individuals who may be at risk of allergic reactions upon exposure to the formulation.

By conducting a comprehensive safety evaluation that includes toxicological considerations, skin irritation potential, and allergenicity assessment, developers can ensure that the topical herbal formulation for managing infectious eczema meets stringent safety standards and minimizes the risk of adverse effects in users. This rigorous safety assessment is essential for obtaining regulatory approval and instilling confidence in healthcare providers and patients regarding the safety and tolerability of the formulation.[29]

IV. EFFICACY EVALUATION

A. Assessment of Anti-inflammatory Properties:

The evaluation of anti-inflammatory properties is essential for determining the efficacy of the topical herbal formulation in managing eczema symptoms. In vitro assays, such as enzyme-linked immunosorbent assays (ELISA) or real-time polymerase chain reaction (PCR), can be used to assess the modulation of pro-inflammatory cytokines and mediators involved in the inflammatory cascade. Additionally, animal models of eczema can be employed to evaluate the suppression of inflammatory responses in vivo. These assessments help elucidate the mechanism of action and anti-inflammatory effects of the herbal formulation.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, May 2024

B. Evaluation of Antimicrobial Activity:

Assessing the antimicrobial activity of the herbal formulation is crucial for targeting infectious agents implicated in eczema exacerbations. In vitro assays, such as agar diffusion or broth microdilution assays, can be utilized to determine the minimum inhibitory concentration (MIC) or zone of inhibition against relevant microbial pathogens, including Staphylococcus aureus and Streptococcus pyogenes. Additionally, ex vivo or in vivo models may be employed to evaluate the formulation's efficacy in reducing microbial colonization and infection within eczematous lesions.

C. Clinical Trials Design and Implementation:

Designing and implementing well-controlled clinical trials are essential for evaluating the clinical efficacy and safety of the topical herbal formulation in human subjects with infectious eczema. Randomized controlled trials (RCTs) with appropriate blinding and placebo controls are preferred to minimize bias and confounding factors. The inclusion of validated outcome measures, such as the Eczema Area and Severity Index (EASI) or SCORing Atopic Dermatitis (SCORAD), allows for standardized assessment of eczema severity and improvement following treatment. Additionally, patient-reported outcomes, including pruritus scores and quality of life assessments, provide valuable insights into treatment efficacy and patient satisfaction.

D. Data Analysis and Interpretation:

Data analysis involves statistical evaluation of clinical trial results to assess the efficacy and safety of the herbal formulation compared to placebo or standard-of-care treatments. Descriptive statistics, such as mean change from baseline and confidence intervals, are calculated to summarize treatment effects. Inferential statistics, including t-tests or analysis of variance (ANOVA), are employed to determine the significance of differences between treatment groups. Furthermore, subgroup analyses and sensitivity analyses may be conducted to explore treatment effects in specific patient populations or to assess the robustness of results. The interpretation of trial findings should consider both statistical significance and clinical relevance, taking into account the magnitude of treatment effects and potential limitations of the study design.

By systematically evaluating the anti-inflammatory properties, antimicrobial activity, and clinical efficacy of the topical herbal formulation through in vitro assays, preclinical models, and well-designed clinical trials, developers can provide robust evidence supporting its therapeutic benefits for managing infectious eczema. This comprehensive efficacy evaluation is essential for informing clinical practice and guiding treatment decisions for eczema patients.[30-35]

V. DISCUSSION

A. Summary of Findings:

The discussion begins with a concise summary of the key findings from the efficacy evaluation of the topical herbal formulation for managing infectious eczema. This includes a recapitulation of the formulation's anti-inflammatory properties, antimicrobial activity, and clinical efficacy as demonstrated through preclinical and clinical studies. The summary highlights the main outcomes and significant findings that contribute to our understanding of the formulation's therapeutic potential in eczema management.

B. Comparison with Conventional Treatments:

A comparative analysis is conducted to contrast the efficacy and safety profile of the topical herbal formulation with conventional treatments commonly used for infectious eczema, such as topical corticosteroids and antimicrobial agents. This comparison examines factors such as treatment effectiveness, onset of action, duration of remission, adverse effects, and patient preference. By juxtaposing the herbal formulation against standard-of-care therapies, the discussion provides insights into its relative merits and limitations in clinical practice.

C. Implications for Clinical Practice:

The discussion explores the implications of the study findings for clinical practice and patient care. This involves considering the potential role of the topical herbal formulation as a therapeutic option for managing infectious eczema in real-world settings. Key considerations include its efficacy, safety, tolerability, ease of use, and cost-effectiveness

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, May 2024

compared to existing treatments. Additionally, practical recommendations are provided for healthcare providers regarding patient selection, treatment initiation and monitoring, and integration into eczema management algorithms.

D. Limitations and Future Directions:

The discussion acknowledges the limitations of the study and identifies areas for future research and development. This may include limitations related to study design, sample size, patient population, duration of follow-up, and outcome measures. Additionally, potential confounding factors, biases, and sources of variability are discussed to contextualize the study findings. Suggestions for future research directions may involve conducting larger-scale clinical trials, exploring novel herbal combinations or formulations, investigating mechanisms of action, addressing safety concerns, and optimizing treatment protocols. By critically evaluating the study's limitations and proposing avenues for further investigation, the discussion contributes to the advancement of knowledge and informs future research endeavors in the field of eczema management.

Through a comprehensive discussion that summarizes the study findings, compares them with conventional treatments, delineates implications for clinical practice, and identifies limitations and future directions, the review provides a holistic interpretation of the topical herbal formulation's efficacy and potential in managing infectious eczema. This synthesis of evidence facilitates evidence-based decision-making and informs healthcare providers, researchers, and patients about the therapeutic options available for eczema management.

VI. CONCLUSION

A. Recap of Key Points:

The conclusion begins by summarizing the key findings and insights generated from the review of the topical herbal formulation for managing infectious eczema. This recapitulation highlights the formulation's efficacy in addressing eczema symptoms, its safety profile, and its potential as an alternative or adjunctive therapy to conventional treatments. The key points serve to reinforce the significance of the study findings and their implications for eczema management.

B. Potential Impact on Eczema Management:

The conclusion discusses the potential impact of the topical herbal formulation on the landscape of eczema management. This involves considering its role in improving patient outcomes, enhancing treatment options, and addressing unmet needs in eczema care. The formulation's potential to offer a natural, holistic, and well-tolerated approach to eczema management is highlighted, along with its ability to complement existing therapies and provide personalized treatment solutions for patients.

C. Recommendations for Further Research:

The conclusion offers recommendations for future research aimed at advancing our understanding of herbal therapies in eczema management. This may include conducting additional clinical trials to further validate the efficacy and safety of the topical herbal formulation, particularly in diverse patient populations and real-world settings. Moreover, recommendations for mechanistic studies, pharmacokinetic assessments, long-term safety monitoring, and health economic evaluations are proposed to address knowledge gaps and optimize the formulation's clinical utility. By providing guidance for future research endeavors, the conclusion contributes to the ongoing exploration and development of herbal therapies for eczema.

In summary, the conclusion underscores the importance of the topical herbal formulation as a promising therapeutic option for managing infectious eczema. It emphasizes the formulation's potential to make a meaningful impact on eczema management practices and calls for continued research efforts to further elucidate its therapeutic benefits and optimize its clinical use. Through concerted efforts in research, innovation, and collaboration, the topical herbal formulation holds promise as a valuable addition to the armamentarium of treatments available for eczema patients.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, May 2024

REFERENCES

[1] Bieber, T. (2008). Mechanisms of disease: Atopic dermatitis. *New England Journal of Medicine, 358*(14), 1483-1494.

[2] Silverberg, J. I., & Hanifin, J. M. (2021). Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study. *Journal of Allergy and Clinical Immunology, 148*(4), 996-1006.

[3] Weidinger, S., & Novak, N. (2016). Atopic dermatitis. *The Lancet, 387*(10023), 1109-1122.

[4] Drucker, A. M., Wang, A. R., & Qureshi, A. A. (2017). Research gaps in quality of life and economic burden of atopic dermatitis: The National Eczema Association burden of disease audit. *JAMA Dermatology, 153*(8), 810-816.

[5] Lin, T. K., Zhong, L., & Santiago, J. L. (2017). Anti-inflammatory and skin barrier repair effects of topical application of some plant oils. *International Journal of Molecular Sciences, 19*(1), 70.

[6] Sidbury, R., Davis, D. M., Cohen, D. E., & Eichenfield, L. F. (2014). Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. *Journal of the American Academy of Dermatology, 71*(2), 327-349.

[7] Kostić, M., Čvorović, A., Kojić-Damjanov, S., Đorđević, S., & Vukasinović, S. (2014). Herbal therapy in dermatology. *Srpski Arhiv za Celokupno Lekarstvo, 142*(5-6), 347-350.

[8] Srivastava, J. K., Shankar, E., & Gupta, S. (2010). Chamomile: A herbal medicine of the past with a bright future. *Molecular Medicine Reports, 3*(6), 895-901.

[9] Sur, R., & Nigam, A. (2010). Gassericin A: A circular bacteriocin produced by Lactobacillus gasseri. *World Journal of Microbiology and Biotechnology, 26*(2), 371-377.

[10] Huang, T. H., Tran, V. H., Duke, R. K., Tan, S., Chrubasik, S., Roufogalis, B. D., & Duke, C. C. (2005). Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kB activation. *Journal of Ethnopharmacology, 100*(1-2), 76-83.

[11] Ernst, E. (2003). Serious adverse effects of unconventional therapies for children and adolescents: A systematic review of recent evidence. *European Journal of Pediatrics, 162*(2), 72-80.

[12] Gilani, A. H., Khan, A. U., Raoof, M., Ghayur, M. N., Siddiqui, B. S., Vohra, W., & Begum, S. (2008). Gastrointestinal, selective airways and urinary bladder relaxant effects of Hyoscyamus niger are mediated through dual blockade of muscarinic receptors and Ca2+ channels. *Fundamental & Clinical Pharmacology, 22*(1), 87-99.

[13] Liu, J., Pei, M., Zheng, C., Li, Y., & Wang, Y. (2007). Antioxidant activity of Cryptomeria japonica D. Don (Taxodiaceae) extracts and identification of the major antioxidant constituents. *Phytotherapy Research, 21*(11), 1175-1179.

[14] Sivasankaran, K., Selvan, A., Balachandran, S., & Ganguly, S. (2009). Anti-inflammatory and antipyretic activities of Boerhaavia diffusa Linn. *Indian Journal of Pharmacology, 41*(2), 75.

[15] Ali, M. S., Jahangir, M., Hussan, M., & Hussain, M. (2013). Effect of Hypericum perforatum in 2, 4, 6-trinitrobenzene sulfonic acid induced colitis in rats. *Journal of Gastroenterology and Hepatology Research, 2*(8), 697-702.

[16] Wang, L., Zhang, S., Cheng, H., Lv, H., & Cheng, G. (2014). Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor. *BMC Complementary and Alternative Medicine, 14*(1), 89.

[17] Sowbhagya, H. B. (2013). Chemistry, technology, and nutraceutical functions of celery (Apium graveolens L.): An overview. *Critical Reviews in Food Science and Nutrition, 53*(4), 389-346.

[18] Jayaprakasha, G. K., Rao, L. J., & Sakariah, K. K. (2003). Chemistry and biological activities of C. longa. *Trends in Food Science & Technology, 16*(12), 533-548.

[19] Muthu, K., Krishnan, N., Sivashanmugam, A., & Pandian, S. K. (2013). Phenol and flavonoid content of flowers of Plumeria alba. *Asian Journal of Pharmaceutical and Clinical Research, 6*(3), 236-238.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, May 2024

[20] Lopes, A. L., Batista, R. O., Souza, A. M., Da Silva, E. R., & Silva, A. F. (2014). Chemical composition and biological activities of the essential oils from leaves of Moringa oleifera Lam. cultivated in Brazil. *Brazilian Journal of Pharmacognosy, 24*(3), 279-284.

[21] Hanifin, J. M., & Rajka, G. (1980). Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica, 92(144), 44-47.

[22] Leung, D. Y., & Guttman-Yassky, E. (2014). Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches. The Journal of Allergy and Clinical Immunology, 134(4), 769-779.

[23] Boguniewicz, M., & Leung, D. Y. (2011). Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunological Reviews, 242(1), 233-246.

[24] Sidbury, R., & Tom, W. L. (2018). Update on the pathogenesis and management of pediatric atopic dermatitis. Seminars in Cutaneous Medicine and Surgery, 37(2), 87-92.

[25] Brunner, P. M., & Guttman-Yassky, E. (2015). Racial differences in atopic dermatitis. Annals of Allergy, Asthma & Immunology, 115(3), 214-218.

[26] Barbarot, S., Auziere, S., Gadkari, A., & Girolomoni, G. (2018). Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy, 73(6), 1284-1293.

[27] Abramovits, W., & Boguniewicz, M. (2005). Adult-onset atopic dermatitis. Journal of the American Academy of Dermatology, 52(4), 579-582.

[28] Katayama, I., Aihara, M., Ohya, Y., Saeki, H., Shimojo, N., Shoji, S., ... & Inomata, N. (2018). Japanese guidelines for atopic dermatitis 2017. Allergology International, 67(2), 139-146.

[29] Thaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., ... & Kabashima, K. (2019). Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). Journal of Dermatological Science, 94(2), 266-275.

[30] Weidinger, S., Novak, N., Grp, A. T., & Grp, T. T. S. (2020). Atopic dermatitis. The Lancet, 396(10247), 345-360.

[31] Silverberg, J. I., Simpson, E. L., Thyssen, J. P., & Weidinger, S. (2020). A clinician's guide to the diagnosis and treatment of atopic dermatitis in adults. Journal of the American Academy of Dermatology, 82(3), 588-601.

[32] Bieber, T., D'Erme, A. M., & Akdis, C. A. (2020). T helper cell differentiation and subsets in eczema. Frontiers in Immunology, 11, 125.

[33] Katayama, I., Kohno, Y., Akiyama, M., Aihara, M., Ikezawa, Z., Adachi, M., ... & Furue, M. (2014). Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries. Allergology International, 63(4), 455-463.

[34] David Boothe, W., Tarbox, J. A., & Tarbox, M. B. (2017). Atopic dermatitis: Pathophysiology. Advances in Experimental Medicine and Biology, 1027, 21-37.

[35] Hijnen, D., Knol, E. F., Gent, R. V., Jakasa, I., Loh, L., Estelle, F., ... & Bruijnzeel-Koomen, C. A. (2013). CD8+ T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22. Journal of Investigative Dermatology, 133(4), 973-979.